Loading...
A Pilot Study of Liposomal Doxorubicin Combined with Bevacizumab followed by Bevacizumab Monotherapy in Patients with Advanced Kaposi Sarcoma
BACKGROUND: Vascular endothelial growth factor A (VEGF-A) is important in the pathogenesis of Kaposi sarcoma (KS), and bevacizumab has response rate of 31%. We explored the combination of bevacizumab with liposomal doxorubicin in patients with KS. METHODS: KS patients requiring systemic therapy were...
Saved in:
| Published in: | Clin Cancer Res |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
2019
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6635024/ https://ncbi.nlm.nih.gov/pubmed/30979736 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-3528 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|